Cryo-Cell receives NYSE American compliance plan acceptance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American
May 8, 2026 4:00 PM EDTOLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced that the NYSE American LLC (the NYSE American") has accepted the Companys previously submitted plan to regain compliance with continued listing standards.
As previously disclosed on March 12, 2026, the Company was notified that it was not in compliance with Section 1003 (a) of the NYSE American Company Guide because the Company reported (i) a stockholders deficit as of November 30, 2025, and (ii) net... More
